Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II selinexor + bortezomib + dexamethasone study in progressive or refractory multiple myeloma
2014-002444-40Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in multiple myeloma (MM) (3 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicity and Recommended dose level. Started Oct 2014; status: active.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-002444-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002444-40.